Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation

Status Completed

Clinical Trial Summary

The overall aim of the clinical investigation is to confirm clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion - Page 1 of 5 - app with TBL Backend when used by subjects with diabetes in need of insulin treatment. Primary objective: To assess diabetes treatment satisfaction in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend Secondary objective: To assess clinical performance and treatment adherence in subjects with diabetes type 1 or type 2 in need of insulin treatment when using Actiste 1.0 and the Companion app with TBL Backend

Clinical Trial Description

This is a prospective, single-arm, post-market clinical investigation to verify clinical performance, treatment satisfaction, adherence and safety of Actiste 1.0 and the Companion app with TBL Backend, referred to as Actiste diabetes management system (ADMS) when used as intended by subjects diagnosed with Diabetes Mellitus Type 1 or Type 2 (T1DM or T2DM). In total, 70 subjects diagnosed with T1DM or T2DM (35 subjects per type) using Glargine U100 basal insulin with or without oral antidiabetic drugs/bolus insulin regimen will be enrolled at 1 site in the UK. Each subject will be evaluated during a period of 6 months. Eight (8) visits are planned for each subject during the clinical investigation, including 3 visits to the study clinic and 5 visits conducted as telephone calls. During the visits, evaluations will be performed to assess blood glucose levels, adherence to the treatment plan, quality of life and treatment satisfaction. Data on blood glucose values, insulin injections and diabetesrelated data from the Companion app and TBL Backend will be shared by the subject.Each participant will be provided with the ADMS, including Actiste 1.0, and the Companion app for their smartphone with the TBL Backend. No comparator will be used. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05284071
Study type	Interventional
Source	Northern Care Alliance NHS Foundation Trust
Contact
Status	Completed
Phase	N/A
Start date	March 14, 2022
Completion date	December 21, 2022

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05437913` - Protocol for Self-Compassion Intervention for Teens With Diabetes Type 1 and Their Caregivers	N/A
Recruiting	`NCT03565770` - Assessment of Individual Follow-up by Coaching Program for Type 1 Diabetes Children	N/A
Not yet recruiting	`NCT06437782` - Exploration of Health Literacy in Diabetes in Reunion Island and France
Not yet recruiting	`NCT05990933` - Role of Adrenaline in in the Inflammatory Response in Diabetes	N/A
Recruiting	`NCT05669547` - Dual Hormone Closed Loop in Type 1 Diabetes	N/A
Completed	`NCT03751007` - A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)	Phase 1/Phase 2
Recruiting	`NCT06190756` - Impact of Gravity on Cardiac Hemodynamics	N/A
Completed	`NCT05069727` - Simple Initiation of Advanced Hybrid Closed Loop System	N/A
Recruiting	`NCT06460558` - T1D Closed-loop and Physical Activity
Recruiting	`NCT05866536` - Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years	Phase 2
Not yet recruiting	`NCT06405373` - Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes	N/A
Not yet recruiting	`NCT06405386` - Pilot of Pragmatic Delivery of Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes	N/A
Completed	`NCT04635280` - Evaluation of Satisfaction Regarding Home Healthcare Provider (HHP) Management of Type 1 Diabetic Patients Using a Closed-loop Automatic Insulin Delivery System	N/A
Completed	`NCT05168657` - Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth	N/A
Active, not recruiting	`NCT05574062` - Evaluation of the MiniMed 780 System in Paediatric Subjects	N/A
Recruiting	`NCT05180591` - Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes	Phase 2
Recruiting	`NCT05176795` - Host-microbiota-environment Interactions
Completed	`NCT05933460` - Crocus Sativus Extract Impact in Metabolic Control of Patients With Diabetes Mellitus Type 1	N/A
Not yet recruiting	`NCT04772729` - Does the Use of Fiasp vs. Asp Lead to the Prolonged TIR in Children With Type 1 Diabetes?	Phase 4
Not yet recruiting	`NCT03170089` - Oral Health Awareness and Oral Hygiene in Insulin Dependent Diabetes Mellitus	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Actiste® Diabetes Management as a Service (ADMS) Clinical Investigation — ADMSUK01

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms